Literature DB >> 9131462

Prevalence and risk factor analysis of GBV-C/HGV infection in prostitutes.

J C Wu1, W Y Sheng, Y H Huang, S J Hwang, S D Lee.   

Abstract

GB virus-C (GBV-C) and Hepatitis G virus (HGV) are variants of a recently cloned virus transmitted parenterally. It is unclear if sexual contact also transmits this virus. In this study, we detected serum GBV-C/HGV RNA in 140 prostitutes by reverse transcription polymerase chain reaction (RT-PCR) using different primers. Thirty (21%) were found with GBV-C RNA by nested PCR although only 22 (73%) had HGV RNA by single round RT-PCR. Both assays had a nearly perfect agreement (kappa value, 0.812). The prevalence of GBV-C RNA in prostitutes was significantly higher than the control group (30/140 vs. 2/40, P < 0.02). Multivariate analysis revealed that a frequency of paid sex more than 120 times per month was the only factor significantly associated with positive GBV-C RNA in prostitutes (P < 0.003). In summary, prostitutes are a high risk group and reservoir of GBV-C/HGV infection due to high frequency of paid-sex.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131462

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  The serological prevalence and risk factor analysis of hepatitis G virus infection in Hubei Province of China.

Authors:  De-Ying Tian; Dao-Feng Yang; Ning-Shao Xia; Zheng-Gang Zhang; Hong-Bo Lei; Yuan-Cheng Huang
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 2.  GB virus C/hepatitis G virus (GBV-C/HGV): still looking for a disease.

Authors:  M Sathar; P Soni; D York
Journal:  Int J Exp Pathol       Date:  2000-10       Impact factor: 1.925

3.  Clinical course of chronic hepatitis C virus infection is not influenced by concurrent hepatitis G virus infection.

Authors:  J Hayashi; K Ueno; Y Kawakami; Y Kishihara; I Ariyama; N Furusyo; Y Sawayama; Y Etoh; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

Review 4.  Sexual transmission and prevention of the hepatitis viruses A-E and G.

Authors:  M G Brook
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

5.  Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells.

Authors:  J Xiang; S Wünschmann; W Schmidt; J Shao; J T Stapleton
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia.

Authors:  I E Souza; J B Allen; J Xiang; D Klinzman; R Diaz; S Zhang; K Chaloner; D Zdunek; G Hess; C F Williams; L Benning; J T Stapleton
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

7.  Lower hepatitis G virus infection prevalence compared to hepatitis B and C virus infection prevalences.

Authors:  N Furusyo; J Hayashi; I Ariyama; Y Sawayama; Y Etoh; S Kashiwagi
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

8.  Hepatitis G virus in the general population and in patients on hemodialysis.

Authors:  J Hayashi; N Furusyo; Y Sawayama; Y Kishihara; Y Kawakami; I Ariyama; Y Etoh; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

9.  Prevalence of GB virus type C viraemia in MSM with or without HIV-1 infection in Beijing, China.

Authors:  Z Liu; L Li; Z Chen; M Xu; T Zhang; Y Jiao; B Sheng; D Chen; H Wu
Journal:  Epidemiol Infect       Date:  2012-03-26       Impact factor: 4.434

10.  Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.

Authors:  David Bonsall; William F Gregory; Camilla L C Ip; Sharyne Donfield; James Iles; M Azim Ansari; Paolo Piazza; Amy Trebes; Anthony Brown; John Frater; Oliver G Pybus; Phillip Goulder; Paul Klenerman; Rory Bowden; Edward D Gomperts; Eleanor Barnes; Amit Kapoor; Colin P Sharp; Peter Simmonds
Journal:  Emerg Infect Dis       Date:  2016-04       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.